Aliko Scientific SA announced that its wholly-owned Italian subsidiary, Hospitex International S.r.l., has signed an agreement with the Jizzakh branch of the Republican Scientific and Practical Centre specialising in oncology and radiology in Uzbekistan to conduct a feasibility study for a national urinary tract cancer screening programme. The collaboration aims to assess the technical, operational, regulatory, financial, and organisational conditions necessary for the potential launch of a pilot screening programme based on the Urine24 model. Subject to the positive conclusion of the study and the completion of required procedures, the parties plan to evaluate a first implementation phase for an estimated value of approximately €1 million.

Francesco Trisolini, Managing Director of Hospitex International, stated that the agreement confirms growing international interest in Urine24 and recognises Aliko Scientific’s expertise in large-scale oncological diagnostic solutions. The decision by the Uzbek Institute of Oncology to utilise this expertise for a national screening programme aligns with the group's strategy to develop accessible cancer diagnostic solutions in international markets.

The feasibility study, on which work has already begun, will include operational workflow definition, laboratory and logistics assessment, legal and regulatory review, financial modelling, and funding-strategy analysis. Hospitex representatives will conduct an in-country mission as part of the assignment. Upon completion, Hospitex will deliver an Operational Project Document to support institutional review and the potential structuring of the next phase.

Urine24 is the screening model developed by Hospitex International to facilitate the early detection of urinary tract cancers through a modular and scalable pathway. The model is adapted for deployment in healthcare systems with varying levels of infrastructure and diagnostic capabilities.

This collaboration follows an institutional visit to Hospitex’s headquarters, organised as part of the Health Study Tour promoted by the Italian Trade Agency (ICE), with the participation of healthcare delegations from Asian countries.

Key Details of the Agreement